Olsutamig is a bivalent humanized IgG4kappa monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells[1][2].
CAS Nummer:
[3034664-43-9]
Target-Kategorie:
CD3,PSMA
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
